Skip to main content

Teleflex Incorporated (TFX) Stock Analysis

Range Bound setup

SellModerate Confidence

Healthcare · Medical Instruments & Supplies

Earnings in 7 days (2026-05-07). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Analyst target reached at $124.31 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 7 days (event risk).

Teleflex designs and manufactures single-use medical devices for critical care and surgical applications globally, selling through direct sales force and distributors to hospitals and healthcare providers. Executing strategic transformation via planned divestitures of Acute... Read more

$124.31+10.2% A.UpsideScore 4.8/10#21 of 25 Medical Instruments & Supplies
Stop $115.55Target $136.88(resistance)A.R:R -0.8:1
Analyst target$132.78+6.8%9 analysts
$136.88our TP
$124.31price
$132.78mean
$115
$147

Sell if holding. Analyst target reached at $124.31 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 7 days (event risk). Chart setup: RSI 56 mid-range, Bollinger mid-band. Score 4.8/10, moderate confidence.

Passes 3/6 gates (clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 7d<=7d. Suitability: moderate.

Thesis

Rewards
Strong earnings beat streak (3/4)
Risks
Analyst target reached - limited upside remaining
Earnings in 7 days (event risk)
Weak overall score: 4.8/10

Key Metrics

P/E (TTM)101.8
P/E (Fwd)12.9
Mkt Cap$5.9B
EV/EBITDA17.7
Profit Mgn-45.4%
ROE1.6%
Rev Growth
Beta0.83
Dividend1.02%
Rating analysts17

Quality Signals

Piotroski F8/9

Options Flow

P/C0.08bullish
IV55%elevated
Max Pain$95-23.6% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMCustomerU.S. distributors
    10-K Item 1A: 'A significant portion of our revenues in the U.S. is derived from sales to distributors'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
2.0
Value Rank
2.4
Growth Rank
5.0

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Volume
0.1
Obv
1.0
Rsi
5.5
Ma Position
6.0
Volume distribution (falling OBV)Above 200-day MA
GatesMomentum 2.5<4.5A.R:R -0.8=NEGATIVEEARNINGS PROXIMITY 7d<=7dInsider activity: OKNo SEC red flagsSEMI CYCLE PEAK CLEARRange BoundSuitability: Moderate
RSI
56 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $114.24Resistance $139.67

Price Targets

$116
$137
A.Upside+10.1%
A.R:R-0.8:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (-7.0% upside)
! Momentum score 2.5/10 — below 4.5 minimum
! Negative risk/reward — downside exceeds upside

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-05-07 (7d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is TFX stock a buy right now?

Sell if holding. Analyst target reached at $124.31 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 7 days (event risk). Chart setup: RSI 56 mid-range, Bollinger mid-band. Prior stop was $115.55. Score 4.8/10, moderate confidence.

What is the TFX stock price target?

Take-profit target: $136.88 (+10.2% upside). Prior stop was $115.55. Stop-loss: $115.55.

What are the risks of investing in TFX?

Analyst target reached - limited upside remaining; Earnings in 7 days (event risk); Weak overall score: 4.8/10.

Is TFX overvalued or undervalued?

Teleflex Incorporated trades at a P/E of 101.8 (forward 12.9). TrendMatrix value score: 5.8/10. Verdict: Sell.

What do analysts say about TFX?

17 analysts cover TFX with a consensus score of 3.3/5. Average price target: $133.

What does Teleflex Incorporated do?Teleflex designs and manufactures single-use medical devices for critical care and surgical applications globally,...

Teleflex designs and manufactures single-use medical devices for critical care and surgical applications globally, selling through direct sales force and distributors to hospitals and healthcare providers. Executing strategic transformation via planned divestitures of Acute Care, IU, and OEM businesses for $2.0B combined, expected to close 2H 2026.

Related stocks: WST (West Pharmaceutical Services, I) · MMSI (Merit Medical Systems, Inc.) · STVN (Stevanato Group S.p.A.) · RMD (ResMed Inc.) · ATRC (AtriCure, Inc.)